RxDoctor Payments Data

Alyssa Johnston, NP

Family · Roseville, CANPI 1891281432

Payments from drug & device makers

$3,076in general payments, 2019–2025

Across 124 payments — averaging $24.80 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$565
  • AbbVie$443
  • Abbott$330
  • Corcept Therapeutics$262
  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$220
  • Esperion Therapeutics, Inc.$151
  • plus $1K from 21 others

What the payments were for

  • Food & beverage$3,076100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,076 in reported general payments places this provider in the 90th percentile of 10,634 family providers in California.

See all family providers in California

Medicare billing

Part B allowed, 2024
$632,526
Medicare patients
168
Services billed
984

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban44$37,698
JardianceEmpagliflozin31$26,138
XareltoRivaroxaban14$9,300
Fluticasone Propionate HfaFluticasone Propionate12$3,239
Rosuvastatin Calcium35$1,789
Duloxetine Hcl18$1,552
Atorvastatin Calcium71$1,065
Quetiapine Fumarate34$932
Memantine Hcl28$873
Donepezil Hcl37$730
Divalproex Sodium33$697
Pantoprazole Sodium20$670
Ulticare Pen NeedlePen Needle, Diabetic11$655
Midodrine Hcl11$641
Montelukast Sodium40$633

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$55$37,69844 claims
Boehringer IngelheimJardiance$59$26,13831 claims
Lilly USA, LLCOlanzapine$34$19311 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 10,634 family providers in California.

Other family in Roseville

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →